Formulation and Drug Delivery, Inhalation Drugs

Stevanato Group and Recipharm to Collaborate on Pre-fillable Syringes for Soft Mist Inhaler

March 17, 2023

Stevanato Group will support development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.

Inhalation Vaccine Development

January 03, 2023

Inhaled vaccines must resist degradation and penetrate the mucosal lining in the airways and lungs.

Delivering a Difference in Formulation

September 03, 2022

It is possible to overcome some of the limitations of traditional dosage forms by employing alternative drug delivery formulation strategies.

Inhalation Formulation Development: Predicting API Behavior

May 03, 2022

Inhalation formulations are complex, and empirical data are essential for realizing optimal solutions.

Taking an Alternative Approach to Drug Delivery

November 03, 2021

Alternative drug delivery approaches are promising, but due to their complexity, they need to be sufficiently justified.

Considerations for DPIs and MDIs in Inhalation Drug Delivery

October 15, 2021

Experts share best practices in designing, manufacturing, and scaling up dry powder inhaler and metered dose inhaler drug–device combination products for inhalation drug delivery.

Best Practices in Manufacturing Inhalation Drugs

September 13, 2021

When designing and manufacturing a pMDI or DPI combination drug-delivery device, the commercial stage should be kept in mind from the beginning of development.

Getting a Nose for Vaccines

September 03, 2021

The intranasal route of administration is showing clinical promise, particularly for COVID-19, but there are multiple hurdles to overcome to ensure successful formulation.

FDA Grants Orphan Drug Designation to Aerami Therapeutics’s Imatinib

August 27, 2021

FDA granted orphan drug designation for imatinib in AER-901 for the treatment of patients with pulmonary arterial hypertension.

Integrated Approach Facilitates Inhalation Drug Development

August 01, 2021

The choice of delivery platform for inhaled drug products is contingent on API-related factors, as well as the development stage of the product.